The high affinity selectin glycan ligand C2-O-sLex and mRNA transcripts of the core 2 β-1,6-N-acetylglusaminyltransferase (C2GnT1) gene are highly expressed in human colorectal adenocarcinomas
© St Hill et al; licensee BioMed Central Ltd. 2009
Received: 11 August 2008
Accepted: 06 March 2009
Published: 06 March 2009
The metastasis of cancer cells and leukocyte extravasation into inflamed tissues share common features. Specialized carbohydrates modified with sialyl Lewis x (sLex) antigens on leukocyte membranes are ligands for selectin adhesion molecules on activated vascular endothelial cells at inflammatory sites. The activity of the enzyme core 2 β1,6 N-acetylglucosaminyltransferase (C2GnT1) in leukocytes greatly increases their ability to bind to endothelial selectins. C2GnT1 is essential for the synthesis of core 2-branched O-linked carbohydrates terminated with sLex (C2-O-sLex). Our goal was to determine the expression profiles of C2-O-sLex in the malignant progression and metastasis of colorectal adenocarcinomas. The well characterized CHO-131 monoclonal antibody (mAb) specifically recognizes C2-O-sLex present in human leukocytes and carcinoma cells. Using CHO-131 mAb, we investigated whether C2-O-sLex was present in 113 human primary colorectal adenocarcinomas, 10 colorectal adenomas, 46 metastatic liver tumors, 28 normal colorectal tissues, and 5 normal liver tissues by immunohistochemistry. We also examined mRNA levels of the enzyme core 2 β1,6-N-acetylglucosaminyltransferase (C2GnT1) in 20 well, 15 moderately, and 2 poorly differentiated colorectal adenocarcinomas, and in 5 normal colorectal tissues by using quantitative real-time polymerase chain reactions (RT-PCR).
We observed high reactivity with CHO-131 mAb in approximately 70% of colorectal carcinomas and 87% of metastatic liver tumors but a lack of reactivity in colorectal adenomas and normal colonic and liver tissues. Positive reactivity with CHO-131 mAb was very prominent in neoplastic colorectal glands of well to moderately differentiated adenocarcinomas. The most intense staining with CHO-131 mAb was observed at the advancing edge of tumors with the deepest invasive components.
Finally, we analyzed C2GnT1 mRNA levels in 37 colorectal adenocarcinomas and 5 normal colorectal tissues by RT-PCR. Significantly, we observed a greater than 15-fold increase in C2GnT1 mRNA levels in colorectal adenocarcinomas compared to normal colorectal tissues.
C2-O-sLex, detected by the CHO-131 mAb, is a tumor associated antigen whose expression is highly upregulated in colorectal adenocarcinomas and metastatic liver tumors compared to normal tissues. C2-O-sLex is a potentially useful early predictor of metastasis.
The malignant transformation of cells is associated with abnormal glycosylation, which results in the altered expression of carbohydrates on the surface of cancer cells . Aberrant glycosylation profoundly impacts most, if not all processes involved in tumor cell invasion and metastasis. The glycosylation status of specific carbohydrate epitopes can modulate diverse cellular functions such as cell growth, adhesion, signal transduction, and motility. Human carcinomas express high levels of the sialyl Lewis x (sLex) tetrasaccharide, a sialylated and fucosylated carbohydrate antigen, and its isomer sialyl Lea, which are associated with a greatly increased metastatic potential and a poor prognosis [2–7]. In particular, carbohydrate antigens such as sLex are thought to contribute to the metastatic process because sLex levels increase as colorectal adenocarcinomas progress from non-metastatic to metastatic tumors [3, 8]. The status of sLex, but not sLea, in colorectal cancers was shown to be an independent predictive factor for disease recurrence, depth of tumor invasion, and histologic type [9, 10].
C2-O-sLex decorates the human leukocyte mucin P-selectin glycoprotein ligand-1 (PSGL1, CD162) and confers high affinity binding of PSGL-1 to the selectins [19, 20], a mechanism that is crucial for leukocyte migration during inflammatory events. Much stronger bonds are formed when leukocytes expressing cell surface C2-O-sLex bind to selectins than when sLex is present on other glycans. Evidence suggests that similar adhesion events may also occur in the dissemination of tumor cells via the circulatory system [21–24]. In vitro and in vivo studies have demonstrated that carbohydrate determinants, such as sLex, on carcinoma cells are glycan ligands for the selectins [25–29]. Interactions of L-selectin on leukocytes , E- and P-selectin on the vascular endothelium [31–33], and P-selectin on platelets  with their ligands have been implicated to facilitate the metastasis of carcinoma cells. Thus far, however, the importance of C2-O-sLeX in the progression and metastasis of colorectal carcinomas has not been directly examined. As with leukocytes, the expression of C2-O-sLex on carcinoma cells may confer greatly enhanced adhesion to the selectins and promote adherence, extravasation, and metastasis.
Previous studies have reported that C2GnT1 transcripts, and in some instances sLex, were expressed in carcinomas and correlated with vessel invasion, depth of tumor invasion, and metastasis [3, 35–37]. These studies provided indirect evidence that C2-O-sLex may participate in carcinoma progression but this relationship needs to be confirmed by the direct detection of C2-O-sLex on carcinoma cells. Detection of cell surface C2-O-sLex directly demonstrates the functional activity of C2GnT1. This distinction is important because other enzymes can compete with C2GnT1 and prevent the formation of C2-O-sLex in carcinoma cells . Inhibition of C2GnT1 by other enzymes can result in the distribution of sLex on other carbohydrates, including O-glycans, N-glycans and glycolipids, that may have much lower affinities for selecting binding .
Recently, we have extensively characterized the monoclonal antibody (mAb) CHO-131 that specifically recognizes C2-O-sLex . The binding specificity of CHO-131 mAb was evaluated using synthetic glycopeptides modeled after the N-terminus of human PSGL-1 containing precise O-glycan structures . The reactivity of CHO-131 mAb, unlike that of anti-sLex antibodies, requires the functional activity of the glycosyltransferases C2GnT1, α2,3-sialyltransferase, and α1,3-fucosyltransferase and therefore was ideal for addressing our hypothesis [40–42]. CHO-131 mAb is not a function blocking antibody, however, and at high concentrations does not inhibit interactions of leukocyte C2-O-sLex on PSGL1 with P-selectin . We have previously demonstrated that C2-O-sLex was expressed on a colorectal adenocarcinoma cell line that avidly attached to E-selectin . The purpose of this study was to investigate the expression of C2-O-sLex in malignant and benign human colorectal tissues and hepatic metastases. We hypothesized that C2-O-sLex, a high affinity selectin ligand, is abundantly expressed on carcinoma cells and is associated with malignant progression and metastasis of colorectal adenocarcinomas. In our approach, we used RT-PCR and immunohistochemistry to assess the levels of C2GnT1 mRNA and expression of C2-O-sLex in colorectal adenocarcinomas, adenomas, metastatic liver tumors and normal colorectal and liver tissues. We found higher expression of C2-O-sLex and correspondingly high C2GnT1 mRNA levels on colorectal adenocarcinomas compared to normal tissues. We also observed high expression of C2-O-sLex on liver metastases of colorectal adenocarcinomas. Based on these results, we propose that C2-O-sLex is a tumor associated antigen and a potential predictor of tumor progression and metastasis.
All tissues were used in accordance with the University of Minnesota's Institutional Review Board regulations. For the immunohistochemical staining procedures tissue samples were from males and females between the ages of 26 and 82 years. The tissue samples used for the RT-PCR analysis were from males and females between the ages of 31 and 93 years.
CHO-131 mAb is a mouse IgM that binds the glycan structure C2-O-sLex and specifically recognizes the presence of this glycan in human leukocytes and carcinoma cells [40, 43]. Mouse anti-CEA clone Col-1 mAb is a mouse IgG2a (Invitrogen, Carlsbad, CA) that specifically recognizes human carcinoembryonic antigen (CEA) in the cytoplasm and membrane of colorectal adenocarcinoma cells but does not react with normal colorectal tissues or with non-specific cross-reacting antigen. Pre-malignant cells, such as colorectal adenomas, also positively react with anti-CEA mAb. Mouse mAb Ab-3, clone Lu-5 is a mouse IgG1 (Thermo Fisher Scientific, Fremont, CA) and is a broad spectrum anti pan-keratin antibody which reacts with epithelial cells and differentiates epithelial from non-epithelial tumors. CSLEX 1 mAb, obtained from Dr. Bruce Walcheck, is a mouse IgM that recognizes the sLex epitope on the cell membrane.
The secondary antibodies used for CSLEX1 and CHO-131 mAb staining were mu-chain specific horseradish peroxidase (HRP) conjugated goat anti-mouse IgM (Invitrogen, Carlsbad, CA) and mu-chain specific alkaline phosphatase (AP) conjugated goat anti-mouse IgM (Chemicon International Inc., Billerica, MA) respectively. For Lu-5 and CEA staining, gamma-chain specific horseradish peroxidase conjugated goat anti-mouse IgG (Chemicon International Inc., Billerica, MA) was used as a secondary antibody. Mouse IgM, mouse IgG2a and mouse IgG1 (Invitrogen) were used as negative control antibodies for CHO-131, CEA, and Lu-5 mAb staining respectively at the same concentrations as the corresponding primary antibodies.
Tissue sections used for immunohistochemical staining were 4-μm thickness, fixed in 10% neutral buffered formalin, and embedded in paraffin. We stained representative sections from each case with hematoxylin and eosin (H & E) according to standard procedures to evaluate tissue morphology. We examined 113 cases of primary colorectal adenocarcinomas, 46 cases of liver metastasis of colorectal adenocarcinomas, 10 cases of colorectal adenomas, 28 normal colorectal tissues, and 5 normal liver samples from pooled specimens that were obtained commercially from MaxArray colorectal adenocarcinoma/normal tissue microarrays (Invitrogen, Carlsbad, CA); AccuMax colon cancer and liver metastasis of colon cancer arrays (ISU ABXIS Co., Ltd, Seoul, South Korea); and from archived tissues (Tissue Procurement Facility, University of Minnesota, Minneapolis, MN). Serial sections were prepared from tissues stained with CHO-131 mAb of 113 colorectal adenocarcinomas, 38 metastatic liver tumors, 5 sections of normal colonic mucosa, and 5 sections of normal liver, and were stained with CSLEX1 mAb. An additional 21 primary colorectal adenocarcinomas (134 total adenocarcinomas) were stained with CSLEX1 mAb to verify localization of the sLex epitope.
A TissueScan colon cancer tissue qPCR array panel (Origene Technologies, Rockville, MD) was obtained commercially and used for evaluation of mRNA expression of C2GNT1 in colorectal tissues by RT-PCR. The panel consisted of cDNAs from tissue samples of 42 human colorectal adenocarcinomas and 6 normal colorectal tissues that were PCR-ready and normalized with β-actin by the company.
Tissues used in the immunohistochemical staining procedures and those from which mRNA was isolated for the quantitative real time-PCR (RT-PCR) experiments were classified as grades of well differentiated, moderately differentiated, and poorly differentiated that represented the differentiation status of tumor cells.
Tumor sections for all staining procedures were deparaffinized in three changes of xylene, hydrated through 100-70% graded concentrations of ethanol and washed in distilled water and 1× Tris/Tween buffer, pH 7.6. To eliminate non-specific staining, tissue sections were incubated with protein block (ScyTek Laboratories, Logan, UT) for 10 minutes, excess block was removed and primary antibody was immediately applied to sections. Incubations with protein block and primary and secondary antibodies were carried out in a humidified chamber at 27 – 30°C. The remaining staining procedures were performed at room temperature. As negative controls, additional sections from each specimen were prepared by replacing the primary antibody with the corresponding isotype-matched, negative control antibody (Invitrogen, Carlsbad, CA) using similar conditions and antibody concentrations to determine the specificity of antibody binding. The primary antibody was removed by washing in 1× Tris/Tween buffer and secondary antibody was applied to tissue sections. Sections were washed, incubated with the chromagen, and counterstained with Mayer's hematoxylin (Dako, Carpinteria, CA). Sections were washed, dehydrated through 70 – 100% graded alcohols, 100% xylenes, and mounted. Stained sections were evaluated by light microscopy.
To detect C2-O-sLex, tissue sections were stained with CHO-131 mAb at a concentration of 15 μg/ml. It was not necessary to perform antigen retrieval or blocking of endogenous peroxidase activity. CHO-131 mAb was applied to tissue sections for 2 hours. Sections were washed and incubated with mu-chain specific goat anti-mouse IgM-AP secondary antibody (16 μg/ml) for 30 minutes. After washing, tissue sections were incubated with a Vector Red alkaline phosphatase chromagen (Vector Laboratories, Burlingame, CA) for 2 minutes.
For detection of the sLex epitope, antigen retrieval was not performed. Endogenous peroxidase activity was blocked by incubation of sections with 3% hydrogen peroxide in 1× PBS for 15 minutes at room temperature. Tissue sections were stained with CSLEX1 mAb (15 μg/ml) for 2 hours, washed, and incubated with mμ-chain specific goat anti-mouse IgM-HRP (30 μg/ml) antibody for 30 minutes. Sections were washed and 3,3- diaminobenzidinetetrahydrochloride (DAB) chromagen (Vector Laboratories, Burlingame, CA) was applied for 5 minutes.
The HL-60 promyelocytic leukemia cell line (American Type Culture Collection, Manassas, VA) expresses high levels of membrane bound sLex, high C2GnT1 activity , and in our hands expressed high levels of C2-O-sLex. Cytospins of HL-60 cells (3 × 104 cells/sample) were generated using a Shandon-Southern SCA-0031 cytocentrifuge (Sewickley, PA, USA) at a speed of 1000 rpm for 5 minutes and were stained with CSLEX1 and CHO-131 mAbs as positive controls.
As additional positive controls, mouse anti-CEA mAb was used at a concentration of 1.6 μg/ml. Lu-5 mAb was used at a concentration of 0.5 μg/ml. The anti-CEA and Lu-5 mAb staining techniques were performed similarly to that for CSLEX1 mAb with some modifications. Proteinase K (Dako, Carpinteria, CA) was used for antigen retrieval in the Lu-5 but not in the CEA mAb staining procedures according to the manufacturer's instructions. Endogenous peroxidase activity was blocked in both Lu-5 and CEA mAb staining techniques. Tissue sections were incubated with either Lu-5 mAb for 30 minutes or anti-CEA mAb for 60 minutes. Sections were washed and incubated with gamma-chain specific goat anti-mouse IgG-HRP antibody (16 μg/ml) of for 30 minutes. After washing, sections were stained with DAB chromagen for 5 minutes.
Quantitative Real Time-PCR
Specific primers for C2GNT1 (Gen Bank Accession number NM_001490) were designed as follows: the forward primer was 5'-GAT GTC ACC TGG AAT CAG CA-3' and the reverse primer was 5'-GCA GCA ACG TCC TCA GCA T-3'. The cDNAs were amplified in an Applied Biosystems 7500 Real-Time PCR system using a reaction volume of 7.5 μl containing 1× SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) and 15 pmol/μL of each primer. The PCR conditions included one cycle at 95°C for 10 minutes followed by 50 cycles of denaturation at 95°C for 15 seconds; annealing at 58°C for 23 seconds; and extension at 72°C for 35 seconds. The dissociation was performed in cycles of 95°C for 15 seconds; annealing at 60°C for 60 seconds; and extension at 95°C for 15 seconds. The relative amount of C2GNT1 transcripts in each sample was normalized to the house keeping gene β-actin by removing the cycle threshold (Ct) value of β-actin from Ct value of C2GNT1 (ΔCt). The fold difference was calculated by subtracting the ΔCt of the test sample from that of the control sample to give ΔΔCt, and fold difference = 2-ΔΔCt . Absolute transcript expression values for C2GNT1 and β-actin beyond 45 cycles were considered to be below detectable levels and those data were eliminated. Each assay was done in duplicate and melt curves were conducted for each reaction to guarantee that a single product was amplified. The PCR products were further confirmed by gel electrophoresis.
Histologic and RT-PCR Grading System for Tissues
The intensity of CHO-131 mAb staining for C2-O-sLex in immunoreactive tissues was scored using a semiquantitative system from 0+ to 3+. Score 0+, no visible immunostaining; score 1+, mild immunostaining; score 2+, moderate immunostaining; and score 3+, strong immunostaining. A score of 0+ to 1+ indicated low reactivity with CHO-131 mAb and a score of 2+ to 3+ indicated high reactivity. Cells were evaluated in five different high-power field areas for each tissue section. Each tissue specimen was scored independently by two pathologists. Any discordant scores were re-evaluated and scored again on the basis of a consensus opinion.
All statistical analyses were implemented using SAS statistical software, version 9.1. In all statistical tests, a p-value of ≤ 0.05 was considered significant. For analysis of the expression of C2-O-sLex in tissue sections of primary colorectal adenocarcinomas and those carcinomas metastatic to the liver, (as indicated by CHO-131 mAb staining), tissues were grouped as either well, moderately, or poorly differentiated. Malignant tissues were also categorized as low expression (score 0+ to 1+) and high expression (score 2+ to 3+) for C2-O-sLex. The Pearson's chi-square test was applied to groups to test any associations between the categorical variables and odds ratios were calculated by the methods of Cochran, Mantel, and Haenszel. The levels of C2GnT1 mRNA in normal colorectal tissues and in well, moderately, and poorly differentiated colorectal adenocarcinomas, but not in liver tissues, was analyzed using the Kruskal-Wallis test with a 5% significance level. The subgroup comparisons between the well, moderate, and poor groups with the normal group were adjusted by the Bonferroni method.
C2-O-sLexwas detected in colorectal adenocarcinomas and metastatic liver tumors by immunohistochemistry
As colorectal adenocarcinomas progressed from a well to poorly differentiated status, proportionately greater numbers of carcinomas displayed increased areas of solid tumor growth that lacked glandular structures. Eight of 8 poorly differentiated colorectal adenocarcinomas examined demonstrated positive reactivity with CHO-131 mAb. We detected high (2+ to 3+) positive staining in 6 of 8 of these tissues. In two of these 6 positively stained, poorly differentiated adenocarcinomas approximately 95% of the tumor consisted of glandular structures that were highly reactive (3+ intensity) with CHO-131 mAb. An example is shown in Figure 3B. In the remaining 4 poorly differentiated adenocarcinomas, only 5–20% of the neoplastic tissue consisted of glandular structures that were highly reactive with CHO-131 mAb. Instead, the majority of the tumor consisted of non-reactive fibrous tissue. Lastly, we observed low (1+) reactivity with CHO-131 mAb in the remaining 2 of 8 poorly differentiated colorectal adenocarcinomas with minimal glandular structures (less than 10% of the total tumor). Glandular structures in normal colorectal epithelium and in colorectal adenomas did not react with CHO-131 mAb (Figure 2E and Figure 3C, D, E).
In our positive controls, we observed that between 75 – 100% of the total tumor area in all colorectal adenocarcinomas stained positively with the anti-CEA mAb, regardless of differentiation status. In colorectal adenocarcinomas, reactivity with anti-CEA mAb was localized to the luminal and sub-membranous regions of the cytoplasm and the staining pattern mimicked that of CHO-131 mAb staining (Figure 2F). As expected, all colorectal adenomas showed positive reactivity with the anti-CEA mAb in 25 – 50% of the total area of each tissue. A representative colorectal adenoma stained with anti-CEA mAb is shown in Figure 3F. Serial tissue sections of liver metastases of primary colorectal adenocarcinomas that reacted positively with CHO-131 mAb displayed strong positive reactivity with the anti-CEA mAb in similar areas of tissue. In contrast, anti-CEA mAb did not react with normal liver tissues (data not shown). As expected, we observed positive reactivity with the Lu-5 mAb in all normal and malignant colorectal and liver tissues examined (data not shown). In HL-60 cells used as positive controls, the cell membrane and cytoplasm stained strongly (3+ reactivity) with the CHO-131 mAb (data not shown). All tissue specimens stained with isotype matched negative control antibodies were negative for tissue reactivity.
C2-O-sLex was expressed in human primary colorectal adenocarcinomas.
CHO-131 mAb staining reactivity in colorectal adenocarcinomas
C2-O-sLex was expressed in colorectal adenocarcinomas metastatic to the liver.
CHO-131 mAb staining reactivity in metastatic liver tumors
C2-O-sLex was compared to sLex expression in primary colorectal adenocarcinomas and metastatic liver tumors.
Antibody staining reactivity in colorectal adenocarcinomas
Antibody staining reactivity in metastatic liver tumors
C2GnT1 mRNA levels were upregulated in colorectal adenocarcinomas
The C2-O-sLex motif on leukocytes confers much higher affinity binding to the selectins than sLex [19, 20]. Detection of C2GnT1 mRNA transcripts, and in some instances sLex, have been reported to positively correlate with the invasiveness and metastasis of human colorectal, pulmonary, and oral cavity carcinomas [35–37]. These studies indirectly imply that C2-O-sLex expression may be increased on carcinoma cells. However, the presence of the sLex epitope on cells is not always indicative of C2GnT1 gene expression because sLex can decorate other glycoconjugates such as glycoproteins, glycolipids, N-glycans and O-glycans [46–51], that may have different functions from those of C2-O-sLex. The direct detection and evaluation of C2-O-sLex in the progression and metastasis of human colorectal adenocarcinomas has not been performed. We hypothesized that C2-O-sLex – a cell surface expressed high affinity selectin ligand – is expressed on carcinoma cells and is associated with malignant progression and metastasis. Our hypothesis was based on evidence suggesting that similar adhesion mechanisms regulate extravasation of leukocytes and carcinoma cells from the circulatory system into tissues [21–24].
The major findings of our study were that C2-O-sLex, a glycan detected by the CHO-131 mAb, was abundantly present in human colorectal adenocarcinomas and metastatic liver tumors but was absent in colorectal adenomas and normal colorectal and liver tissues. As colorectal adenocarcinomas progressed from well to moderately differentiated status, significantly greater numbers of the tumors examined displayed high levels of C2-O-sLex on the cell surface where more than 50% of the total tumor mass was positive for C2-O-sLex expression. Furthermore, we detected a significant increase (greater than 15-fold) in average C2GnT1 mRNA levels in well and moderately differentiated colorectal adenocarcinomas compared to normal colorectal tissues by RT-PCR. Our findings are novel because, to our knowledge, we are the first to provide direct evidence that C2-O-sLex on colorectal adenocarcinomas is a tumor antigen and that increased expression of C2-O-sLex is associated with more advanced disease.
We detected high expression of C2-O-sLex in the majority (6 of 8) of poorly differentiated adenocarcinomas. We observed the highest C2-O-sLexexpression (3+ staining intensity) in 2 of 6 malignant tissues where over 95% of the tumor mass consisted of neoplastic glandular structures. We also found a 9-fold increase in C2GnT1 mRNA levels in poorly differentiated adenocarcinomas compared to normal colorectal tissues that was not statistically significant. These results were surprising because we expected poorly differentiated adenocarcinomas to have the highest expression of cell surface C2-O-sLex and corresponding upregulation of C2GnT1 mRNA. Poorly differentiated colorectal adenocarcinomas account for 5–10% of all cases of colorectal cancer and are regarded as highly malignant. These tumors can be further classified into solid type and non-solid type patterns of growth where the solid type pattern is predominantly non-glandular. We observed that C2-O-sLex expression is mainly localized to neoplastic glands. In the majority (6 of 8) of the poorly differentiated colorectal adenocarcinomas that we examined there was minimal glandular differentiation compared with well and moderately differentiated adenocarcinomas. This finding is a likely explanation for the decrease in C2GnT1 mRNA expression and reactivity with CHO-131 mAb that we observed in poorly differentiated tumors. Because solid type poorly differentiated colorectal adenocarcinomas are associated with a better prognosis compared to the non-solid type , we speculate that the intense reactivity with CHO-131 mAb that we observed in highly glandular non-solid type poorly differentiated colorectal adenocarcinomas is an indicator of a poor prognosis. This possibility remains to be investigated in the future using a larger sample size of this subgroup of tissues. Another possible reason for the decrease in C2GnT1 mRNA levels that we observed in poorly differentiated colorectal adenocarcinomas is that the tissues used for RT-PCR and those used for immunohistochemistry were from different sources and we could not make a direct correlation between C2GnT1 mRNA levels and C2-O-sLex levels in the same patient. The small sample size obtained for the poorly differentiated adenocarcinomas used in the immunohistochemical staining (n = 8) and RT-PCR analysis (n = 2) may be an additional explanation for this discrepancy.
Intestinal mucins are glycoproteins characterized by dense O-glycosylation on serine and threonine amino acids. Colonic mucins have four main O-glycan core structures (1–4). Of these structures, core 2 beta 1,6 branching is critical for biosynthesis of sLex on O-glycans. Core 2 branching can be synthesized by at least three enzymes in the C2GnT family, C2GnT1 or C2Gnt-L (leukocyte-type) , C2GnT2 or C2GnT-M (mucin-type)  and C2GnT3 or C2GnT-T (thymus-associated) [54, 55]. C2GnT-M can form multiple branched structures: core 2 type branching, core 4 type branching, and blood group antigen I. C2GnT-M is highly expressed in healthy colonic mucosa and is replaced by C2GnT-L in colon cancer tissues . Recently, Huang et al. reported that C2GnT-M is downregulated in colorectal cancer and suppresses colon cancer cell growth . In this study the differentiation status of the tumors was not examined. C2GnT-L and C2GnT-M may have distinct but overlapping functions in the progression of colorectal carcinomas. We observed a considerable increase in C2CnT-L expression at the protein and mRNA levels as colorectal carcinomas progressed from well to moderately differentiated. We speculate that in the early stages of colorectal cancer carcinogenesis, C2GnT-M may predominate in colonic tissues with developing malignancy and act as a control mechanism to inhibit the growth of colon cancer cells. As the tumor progresses to more advanced stages, upregulated C2GnT-L activity may predominate and be associated with a corresponding increase in C2-O-sLex expression on colorectal cancer cells. The biochemical pathway of C2-O-sLex synthesis is complex involving several sequential glycosyltransferase reactions. We cannot rule out that other glycosyltransferases in addition to C2GnT1 may also be upregulated in colorectal adenocarcinomas resulting in the increased C2-O-sLex levels that we observed in our study. Nevertheless, our findings indicate that high levels of C2-O-sLex, detected by the CHO-131 mAb, corresponded to measurable upregulation of the C2GnT1 gene as colorectal adenocarcinomas progressed in malignancy.
C2-O-sLex is also present on most leukocytes but this cell type was easily morphologically distinguishable from carcinoma cells by hematoxylin and eosin staining. Furthermore, we performed immunohistochemical staining with the Lu-5 mAb that detects epithelial cells to verify that C2-O-sLex positive malignant cells were epithelial in origin. Thus, we found that the C2-O-sLex antigen on colorectal adenocarcinomas was associated with a more advanced tumor. Similarly to leukocytes, C2-O-sLexmay represent a high affinity glycan ligand for the selectins.
Providing direct evidence for the expression of C2-O-sLex on carcinoma cells is important because this oligosaccharide serves as a high affinity ligand for the selectins during leukocyte migration into sites of inflammation and secondary lymphoid organs. Similarly, C2-O-sLex may function as a high affinity selectin ligand on carcinoma cells that promotes adhesion of malignant cells to endothelium and subsequent metastasis. The direct demonstration of C2-O-sLex on the cell surface is essential because other enzymes such as the glycosyltransferase ST3 beta-galactoside alpha-2,3-sialyltransferase 1 can compete with C2GnT1 in carcinoma cells and inhibit the conversion of core 1 O-glycans to core 2 .
It is well established that levels of sLex increase during progression of colorectal adenocarcinomas from nonmetastatic to metastatic tumors and there is an inverse correlation with postoperative survival . However, a direct investigation of the expression of C2-O-sLex specifically at various stages of malignant colorectal tumor growth and in normal colorectal tissues had not been performed previously. Similarly to leukocytes, expression of C2-O-sLex may promote much greater selectin-mediated adhesiveness of cancer cells to endothelium than sLex on other structures resulting in enhanced metastatic ability. Indeed, we have shown that in two colorectal adenocarcinoma cell lines, the cell line expressing C2-O-sLex, but not the cell line lacking C2-O-sLex, bound avidly to E-selectin under shear stress conditions simulating the vasculature . Importantly, sLex can terminally decorate other cell surface macromolecules that may not be high affinity selectin ligands including proteins containing N-glycans, non-core 2 O-glycans, and glycolipids. Recently, CHO-131 mAb was found to stain a subset of cutaneous lymphocyte-associated antigen (CLA) T cells. P-selectin binding activity was significantly greater for CHO-131+ CLA+ T cells than for CHO-131- CLA+ T cells. C2-O-sLex expression in CLA+ T cells appears to differentially regulate high affinity binding to P-selectin . In colorectal adenocarcinomas, differences in C2-O-sLex expression may similarly regulate adhesion to the selectins and metastasis.
Sialylated Lewis structures such as sLex and sLea are highly expressed on melanomas and various types of carcinomas including colon, gastric, pancreatic, squamous cell, and breast and expression levels correlate with an advanced stage of disease and poor patient prognosis [2–7, 10, 59–62]. Moreover, sLex is a selectin ligand capable of mediating the binding of tumor cells to endothelia, platelets, and neutrophils [25, 28]. It is intriguing to speculate that C2-O-sLex in some instances is the moiety mediating these reported interactions. In particular, C2-O-sLex has recently been shown to be expressed on cutaneous T cell lymphomas and is a ligand for P- and E-selectin . We report here that in colorectal adenocarcinomas and metastatic liver tumors, C2-O-sLex expression was present in similar regions of tissue as that noted for sLex expression but the latter was more widely distributed. This result was expected because CSLEX1 mAb recognizes the sLex epitope alone that can be present on several types of glycan structures including core 2 O-glycans . In contrast, CHO-131 mAb specifically detects sLex on core 2 O-glycans which represents a unique subset of glycoproteins present on tumor cells.
The development of metastasis is an important factor in determining the outcome of patients with colorectal adenocarcinomas. Metastatic involvement of lymph nodes or metastases into distant organs greatly decreases the median patient survival . The liver is the primary site of metastasis for colorectal adenocarcinomas . Interestingly, sLex expression by carcinomas has been proposed to enhance the ability of tumor cells to metastasize to the liver through E-selectin mediated interactions [3, 27, 32, 67] and sLex epitopes are overexpressed in liver metastases of colorectal adenocarcinomas [3, 8, 68]. In our study, all normal liver tissues lacked reactivity with the CHO-131 mAb. We found that 87% (40 of 46) of liver metastases of primary colorectal adenocarcinomas examined stained positively with the CHO-131 mAb. A subset (35 of 40) of these positive tissues exhibited high (2+ to 3+) staining intensity with CHO-131 mAb indicating that C2-O-sLex was abundantly present on metastatic liver tumors. Of note is that liver metastases of primary colorectal adenocarcinomas but not normal liver tissues expressed C2-O-sLex. Our findings suggest that high levels of the C2-O-sLex antigen was preserved on the surface of colorectal adenocarcinomas cells as they migrated from the primary tumor to the liver, a common site of metastasis. We speculate that C2-O-sLex expression may be specifically upregulated during metastasis to promote the metastatic ability of colorectal adenocarcinomas.
In summary, our results demonstrate that C2-O-sLex is highly expressed in colorectal adenocarcinomas and liver metastases but not on benign colorectal and liver tissues. Our observations suggest that upregulation of C2GnT1 gene expression is correlated with increased cell surface expression of C2-O-sLex. C2-O-sLex is an important high-affinity glycan ligand for the selectins on leukocytes and cutaneous T cell lymphomas [16, 17, 19, 20, 63]. Additional research is needed to determine whether C2-O-sLex is a higher-affinity selectin binding ligand than sLex and its function in the progression and metastasis of colorectal adenocarcinomas.
Our observations indicate that C2-O-sLex is a tumor-associated antigen in colorectal adenocarcinomas and metastatic liver tumors. Furthermore, C2-O-sLex expression may represent an early predictor of progression and metastasis of colorectal adenocarcinomas. C2GnT1 is a candidate as a novel target for regulation of C2-O-sLex synthesis and is potentially important therapeutically to control carcinoma dissemination. We are currently investigating the role of carcinoma associated C2-O-sLex compared to sLex in adhesion to the selectins, tumor invasion, and metastasis. We are also examining the usefulness of C2-O-sLex as a practical prognostic tool to predict the long-term survival of cancer patients.
We thank Dr. Karin Matchett for review of the manuscript and members of the University of Minnesota's Masonic Cancer Center Comparative Pathology Shared Resource for assistance with the immunohistochemical procedures. This work was supported in part by funds from the National Institutes of Health, National Cancer Institute grant 5KO8CA111829-03.
- Hakomori S: Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 1996, 56 (23): 5309-5318.PubMedGoogle Scholar
- Irimura T, Nakamori S, Matsushita Y, Taniuchi Y, Todoroki N, Tsuji T, Izumi Y, Kawamura Y, Hoff SD, Cleary KR, Ota DM: Colorectal cancer metastasis determined by carbohydrate-mediated cell adhesion: role of sialyl-Lex antigens. Semin Cancer Biol. 1993, 4 (5): 319-324.PubMedGoogle Scholar
- Nakamori S, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, Sasaki Y, Kabuto T, Iwanaga T, Matsushita Y, Irimura T: Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res. 1993, 53 (15): 3632-3637.PubMedGoogle Scholar
- Kishimoto T, Ishikura H, Kimura C, Takahashi T, Kato H, Yoshiki T: Phenotypes correlating to metastatic properties of pancreas adenocarcinoma in vivo: the importance of surface sialyl Lewis(a) antigen. Int J Cancer. 1996, 69 (4): 290-294. 10.1002/(SICI)1097-0215(19960822)69:4<290::AID-IJC9>3.0.CO;2-S.View ArticlePubMedGoogle Scholar
- Renkonen J, Paavonen T, Renkonen R: Endothelial and epithelial expression of sialyl Lewis(x) and sialyl Lewis(a) in lesions of breast carcinoma. Int J Cancer. 1997, 74 (3): 296-300. 10.1002/(SICI)1097-0215(19970620)74:3<296::AID-IJC11>3.0.CO;2-A.View ArticlePubMedGoogle Scholar
- Nakamori S, Furukawa H, Hiratsuka M, Iwanaga T, Imaoka S, Ishikawa O, Kabuto T, Sasaki Y, Kameyama M, Ishiguro S, Irimura T: Expression of carbohydrate antigen sialyl Le(a): a new functional prognostic factor in gastric cancer. J Clin Oncol. 1997, 15 (2): 816-825.PubMedGoogle Scholar
- Renkonen J, Heinävaara S, Sankila R, Paavonen T: Endothelial and epithelial expression of sialyl Lewis x in squamous carcinoma of the tongue. APMIS. 2000, 108 (10): 705-712. 10.1034/j.1600-0463.2000.d01-18.x.View ArticlePubMedGoogle Scholar
- Hoff SD, Matsushita Y, Ota DM, Cleary KR, Yamori T, Hakomori S, Irimura T: Increased expression of sialyl-dimeric Lex antigen in liver metastases of human colorectal carcinoma. Cancer Res. 1989, 49 (24 Pt 1): 6883-6888.PubMedGoogle Scholar
- Nakamori S, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, Sasaki Y, Izumi Y, Irimura T: Involvement of carbohydrate antigen sialyl Lewis(x) in colorectal cancer metastasis. Dis Colon Rectum. 1997, 40 (4): 420-431. 10.1007/BF02258386.View ArticlePubMedGoogle Scholar
- Izumi Y, Kawamura YJ, Irimura T: Carbohydrate antigens in carcinoma invasion and metastasis. Nippon Geka Gakkai Zasshi. 1996, 97 (2): 140-144.PubMedGoogle Scholar
- Walz G, Aruffo A, Kolanus W, Bevilacqua M, Seed B: Recognition by ELAM-1 of the sialyl-Lex determinant on myeloid and tumor cells. Science. 1990, 250 (4984): 1132-1135. 10.1126/science.1701275.View ArticlePubMedGoogle Scholar
- Foxall C, Watson SR, Dowbenko D, Fennie C, Lasky LA, Kiso M, Hasegawa A, Asa D, Brandley BK: The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewis(x) oligosaccharide. J Cell Biol. 1992, 117 (4): 895-902. 10.1083/jcb.117.4.895.View ArticlePubMedGoogle Scholar
- Li F, Wilkins PP, Crawley S, Weinstein J, Cummings RD, McEver RP: Post-translational modifications of recombinant P-selectin glycoprotein ligand-1 required for binding to P- and E-selectin. J Biol Chem. 1996, 271 (6): 3255-3264. 10.1074/jbc.271.6.3046.View ArticlePubMedGoogle Scholar
- Ramachandran V, Nollert MU, Qui H, Liu WJ, Cummings RD, Zhu C, McEver RP: Tyrosine replacement in P-selectin glycoprotein ligand-1 affects distinct kinetic and mechanical properties of bonds with P- and L-selectin. Proc Natl Acad Sci USA. 1999, 96 (24): 13771-13776. 10.1073/pnas.96.24.13771.View ArticlePubMedPubMed CentralGoogle Scholar
- Epperson TK, Patel KD, McEver RP, Cummings RD: Noncovalent association of P-selectin glycoprotein ligand-1 and minimal determinants for binding to P-selectin. J Biol Chem. 2000, 275 (11): 7839-7853. 10.1074/jbc.275.11.7839.View ArticlePubMedGoogle Scholar
- Ellies LG, S T, Petryniak B, Lowe JB, Fukada M, Marth JD: Core 2 oligosaccharide biosynthesis distinguishes between selectin ligands essential for leukocyte homing and inflammation. Immunity. 1998, 9 (6): 881-890. 10.1016/S1074-7613(00)80653-6.View ArticlePubMedGoogle Scholar
- Sperandio M, Thatte A, Foy D, Ellies LG, Marth JD, Ley K: Severe impairment of leukocyte rolling in venules of core 2 glucosaminyltransferase-deficient mice. Blood. 2001, 97 (12): 3812-3819. 10.1182/blood.V97.12.3812.View ArticlePubMedGoogle Scholar
- Mitsakos A, Hanisch FG, Uhlenbruck G: Biosynthesis of the cancer-associated sialyl-Lex determinant in human amniotic fluid. Biol Chem Hoppe-Seyler. 1988, 369 (8): 661-665.View ArticlePubMedGoogle Scholar
- Leppänen A, Mehta P, Ouyang YB, Ju T, Helin J, Moore KL, van Die I, Canfield WM, McEver RP, Cummings RD: A novel glycosulfopeptide binds to P-selectin and inhibits leukocyte adhesion to P-selectin. J Biol Chem. 1999, 274 (35): 24838-24848. 10.1074/jbc.274.35.24838.View ArticlePubMedGoogle Scholar
- Leppänen A, Yago T, Otto VI, McEver RP, Cummings RD: Model glycosulfopeptides from P-selectin glycoprotein ligand-1 require tyrosine sulfation and a core 2-branched O-glycan to bind to L-selectin. J Biol Chem. 2003, 278 (29): 26391-26400. 10.1074/jbc.M303551200.View ArticlePubMedGoogle Scholar
- Rice GE, Bevilacqua MP: An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. Science. 1989, 246 (4935): 1303-1306. 10.1126/science.2588007.View ArticlePubMedGoogle Scholar
- Hession C, Osborn L, Goff D, Chi-Rosso G, Vassallo C, Pasek M, Pittack C, Tizard R, Goelz S, McCarthy K, Hopple S, Lobb R: Endothelial leukocyte adhesion molecule 1: direct expression cloning and functional interactions. Proc Natl Acad Sci USA. 1990, 87 (5): 1673-1677. 10.1073/pnas.87.5.1673.View ArticlePubMedPubMed CentralGoogle Scholar
- Lafrenie RM, Buchanan MR, Orr FW: Adhesion molecules and their role in cancer metastasis. Cell Biophys. 1993, 23 (1-3): 3-89.View ArticlePubMedGoogle Scholar
- Kim YJ, Borsig L, Han H-L, Varki NM, Varki A: Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium. Am J Pathol. 1999, 155 (2): 461-472.View ArticlePubMedPubMed CentralGoogle Scholar
- Takada A, Ohmori K, Yoneda T, Tsuyuoka K, Hasegawa A, Kiso M, Kannagi R: Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis x to adhesion of human cancer cells to vascular endothelium. Cancer Res. 1993, 53 (2): 354-361.PubMedGoogle Scholar
- Sawada T, Ho JJ, Chung YS, Sowa M, Kim YS: E-selectin binding by pancreatic tumor cells is inhibited by cancer sera. Int J Cancer. 1994, 57 (6): 901-907. 10.1002/ijc.2910570621.View ArticlePubMedGoogle Scholar
- Izumi Y, Taniuchi Y, Tsuji T, Smith C, Nakamori S, Fidler I, Irimura T: Characterization of human colon carcinoma variant cells selected for sialyl Lex carbohydrate antigen: liver colonization and adhesion to vascular endothelial cells. Exp Cell Res. 1995, 216 (1): 215-221. 10.1006/excr.1995.1027.View ArticlePubMedGoogle Scholar
- Mannori G, Crottet P, Cecconi O, Hanasaki K, Aruffo A, Nelson RM, Varki A, Bevilacqua MP: Differential colon cancer cell adhesion to E-, P-, and L-selectin: role of mucin-type glycoproteins. Cancer Res. 1995, 55 (19): 4425-4431.PubMedGoogle Scholar
- Tomlinson J, Wang JL, Barsky SH, Lee MC, Bischoff J, Nguyen M: Human colon cancer cells express multiple glycoprotein ligands for E-selectin. Int J Oncol. 2000, 16 (2): 347-353.PubMedGoogle Scholar
- Borsig L, Wong R, Hynes RO, Varki NM, Varki A: Synergistic effects of L-and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci USA. 2002, 99 (4): 2193-2198. 10.1073/pnas.261704098.View ArticlePubMedPubMed CentralGoogle Scholar
- Dejana E, Martin-Padura I, Lauri D, Bernasconi S, Bani MR, Garofalo A, Giavazzi R, Magnani J, Mantovani A, Menard S: Endothelial leukocyte adhesion molecule-1-dependent adhesion of colon carcinoma cells to vascular endothelium is inhibited by an antibody to Lewis fucosylated type 1 carbohydrate chain. Lab Invest. 1992, 66 (3): 324-330.PubMedGoogle Scholar
- Brodt P, Fallavollita L, Bresalier RS, Meterissian S, Norton CR, Wolitzky BA: Liver endothelial E-selectin mediates carcinoma cell adhesion and promotes liver metastasis. Int J Cancer. 1997, 71 (4): 612-619. 10.1002/(SICI)1097-0215(19970516)71:4<612::AID-IJC17>3.0.CO;2-D.View ArticlePubMedGoogle Scholar
- Kim YJ, Borsig L, Varki NM, Varki A: P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci USA. 1998, 95 (16): 9325-9330. 10.1073/pnas.95.16.9325.View ArticlePubMedPubMed CentralGoogle Scholar
- Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A: Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA. 2001, 98 (6): 3352-3357. 10.1073/pnas.061615598.View ArticlePubMedPubMed CentralGoogle Scholar
- Shimodaira K, Nakayama J, Nakamura N, Hasebe O, Tsutomu K, Fukuda M: Carcinoma-associated expression of core 2 β-1,6-N-acetylglucosaminyltransferase gene in human colorectal cancer: role of O-glycans in tumor progression. Cancer Res. 1997, 57 (23): 5201-5206.PubMedGoogle Scholar
- Machida E, Nakayama J, Amano J, Fukuda M: Clinicopathological significance of core 2 β1,6-N-acetylglucosaminyltransferase messenger RNA expressed in the pulmonary adenocarcinoma determined by in situ hybridization. Cancer Res. 2001, 61 (5): 2226-2231.PubMedGoogle Scholar
- Renkonen J, Räbinä J, Mattila P, Grenman R, Renkonen R: Core 2 β1,6-N-acetylglucosaminyltransferases and α1,3-fucosyltransferases regulate the synthesis of O-glycans on selectin ligands on oral cavity carcinoma cells. APMIS. 2001, 109 (7-8): 500-6. 10.1111/j.1600-0463.2001.apm090703.x.View ArticlePubMedGoogle Scholar
- Dalziel M, Whitehouse C, McFarlane I, Brockhausen I, Gschmeissner S, Schwientek T, Clausen H, Burchell JM, Taylor-Papadimitriou J: The relative activities of the C2GnT1 and ST3Gal-I glycosyltransferases determine O-glycan structure and expression of a tumor-associated epitope on MUC1. J Biol Chem. 2001, 276 (14): 11007-11015. 10.1074/jbc.M006523200.View ArticlePubMedGoogle Scholar
- Fukuda M: Cell surface glycoconjugates as onco-differentiation markers in hematopoietic cells. Biochim Biophys Acta. 1985, 780 (2): 119-150.PubMedGoogle Scholar
- Walcheck B, Leppänen A, Cummings RD, Knibbs RN, Stoolman LM, Alexander SR, Mattila PE, McEver RP: The monclonal antibody CHO-131 binds to a core 2 O-glycan terminated with sialyl-Lewis x, which is a functional glycan ligand for P-selectin. Blood. 2002, 99 (11): 4063-4069. 10.1182/blood-2001-12-0265.View ArticlePubMedGoogle Scholar
- Yago T, Leppanen A, Carlyon JA, Akkoyunlu M, Karmakar S, Fikrig E, Cummings RD, McEver RP: Structurally distinct requirements for binding of P-selectin glycoprotein ligand-1 and sialyl Lewis x to Anaplasma phagocytophilum and P-selectin. J Biol Chem. 2003, 278 (39): 37987-37997. 10.1074/jbc.M305778200.View ArticlePubMedGoogle Scholar
- Smith MJ, Smith BR, Lawrence MB, Snapp KR: Functional analysis of the combined role of the O-linked branching enzyme core 2 beta1-6-N-glucosaminyltransferase and dimerization of P-selectin glycoprotein ligand-1 in rolling on P-selectin. J Biol Chem. 2004, 279 (21): 21984-21991. 10.1074/jbc.M402731200.View ArticlePubMedGoogle Scholar
- St. Hill CA, Bullard KM, Walcheck B: Expression of the high-affinity selectin glycan ligand C2-O-sLeX by colon carcinoma cells. Cancer Lett. 2005, 217 (1): 105-113. 10.1016/j.canlet.2004.06.038.View ArticlePubMedGoogle Scholar
- Fugang L, Wilkins PP, Crawley S, Weinstein J, Cummings RD, McEver RP: Post-translational modifications of recombinant P-selectin glycoprotein ligand-1 required for binding to P- and E-selectin. J Biol Chem. 1996, 271 (6): 3255-3264. 10.1074/jbc.271.6.3255.View ArticleGoogle Scholar
- Ramakers C, Ruijter JM, Deprez RHL, Moorman AFM: Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett. 2003, 339 (1): 62-66. 10.1016/S0304-3940(02)01423-4.View ArticlePubMedGoogle Scholar
- De Graaf TW, Stelt Van der ME, Anbergen MG, van Dijk W: Inflammation-induced expression of sialyl Lewis X-containing glycan structures on alpha 1-acid glycoprotein (orosomucoid) in human sera. J Exp Med. 1993, 177 (3): 657-666. 10.1084/jem.177.3.657.View ArticlePubMedGoogle Scholar
- Easton EW, Schiphorst WE, van Drunen E, Schoot van der CE, Eijnden van den DH: Human myeloid alpha 3-fucosyltransferase is involved in the expression of the sialyl-Lewis(x) determinant, a ligand for E- and P-selectin. Blood. 1993, 81 (11): 2978-2986.PubMedGoogle Scholar
- Ross EL, Barker JN, Allen MH, Chu AC, Groves RW, MacDonald DM: Langerhans' cell expression of the selectin ligand, sialyl Lewis x. Immunology. 1994, 81 (2): 303-308.PubMedPubMed CentralGoogle Scholar
- Katnik I, Goodarzi MT, Turner GA: An improved ELISA for the determination of sialyl Lewis(x) structures on purified glycoconjugates. Glycoconj J. 1996, 13 (6): 1043-1047. 10.1007/BF01053200.View ArticlePubMedGoogle Scholar
- Linden Brinkman-van der EC, de Haan PF, Havenaar EC, van Dijk W: Inflammation-induced expression of sialyl LewisX is not restricted to alpha1-acid glycoprotein but also occurs to a lesser extent on alpha1-antichymotrypsin and haptoglobin. Glycoconj J. 1998, 15 (2): 177-182. 10.1023/A:1006972307166.View ArticleGoogle Scholar
- Zogakis TG, Libutti SK: General aspects of anti-angiogenesis and cancer therapy. Expert Opin Biol Ther. 2001, 1 (2): 253-275. 10.1517/147125126.96.36.199.View ArticlePubMedGoogle Scholar
- Goi T, Hirono Y, Katayama K, Yamaguchi A: Microsatellite instability and survival rate in the solid or nonsolid types of poorly differentiated colorectal adenocarcinoma. Int Surg. 2004, 89 (2): 100-106.PubMedGoogle Scholar
- Bierhuizen MF, Fukuda M: Expression cloning of a cDNA encoding UDP-GlcNAc:Gal beta 1-3-GalNAc-R (GlcNAc to GalNAc) beta 1-6GlcNAc transferase by gene transfer into CHO cells expressing polyoma large tumor antigen. Proc Natl Acad Sci USA. 1992, 89 (19): 9326-9330. 10.1073/pnas.89.19.9326.View ArticlePubMedPubMed CentralGoogle Scholar
- Schwientek T, Nomoto M, Levery SB, Merkx G, van Kessel AG, Bennett EP, Hollingsworth MA, Clausen H: Control of O-glycan branch formation. Molecular cloning of human cDNA encoding a novel beta1,6-N-acetylglucosaminyltransferase forming core 2 and core 4. J Biol Chem. 1999, 274 (8): 4504-4512. 10.1074/jbc.274.8.4504.View ArticlePubMedGoogle Scholar
- Schwientek T, Yeh JC, Levery SB, Keck B, Merkx G, van Kessel AG, Fukuda M, Clausen H: Control of O-glycan branch formation. Molecular cloning and characterization of a novel thymus-associated core 2 beta1, 6-n-acetylglucosaminyltransferase. J Biol Chem. 2000, 275 (15): 11106-11113. 10.1074/jbc.275.15.11106.View ArticlePubMedGoogle Scholar
- Yang JM, Byrd JC, Siddiki BB, Chung YS, Okuno M, Sowa M, Kim YS, Matta KL, Brockhausen I: Alterations of O-glycan biosynthesis in human colon cancer tissues. Glycobiology. 1994, 4 (6): 873-884. 10.1093/glycob/4.6.873.View ArticlePubMedGoogle Scholar
- Huang M-C, Chen H-Y, Huang H-C, Huang J, Liang J-T, Shen T-L, Lin N-Y, Ho C-C, Cho I-M, Hsu S-M: C2GnT-M is downregulated in colorectal cancer and its re-expression causes growth inhibition of colon cancer cells. Oncogene. 2006, 25 (23): 3267-3276. 10.1038/sj.onc.1209350.View ArticlePubMedGoogle Scholar
- Ni Z, Campbell JJ, Niehans G, Walcheck B: The monoclonal antibody CHO-131 identifies a subset of cutaneous lymphocyte-associated antigen T cells enriched in P-selectin-binding cells. J Immunol. 2006, 177 (7): 4742-4748.View ArticlePubMedGoogle Scholar
- Allen MH, Robinson MK, Stephens PE, MacDonald DM, Barker JN: E-selectin binds to squamous cell carcinoma and keratinocyte cell lines. J Invest Dermatol. 1996, 106 (4): 611-615. 10.1111/1523-1747.ep12345385.View ArticlePubMedGoogle Scholar
- Bresalier RS, Ho SB, Schoeppner HL, Kim YS, Sleisenger MH, Brodt P, Byrd JC: Enhanced sialylation of mucin-associated carbohydrate structures in human colon cancer metastasis. Gastroenterology. 1996, 110 (5): 1354-1367. 10.1053/gast.1996.v110.pm8613039.View ArticlePubMedGoogle Scholar
- Ravindranath MH, Amiri AA, Bauer PM, Kelley MC, Essner R, Morton DL: Endothelial-selectin ligands sialyl Lewis(x) and sialyl Lewis(a) are differentiation antigens immunogenic in human melanoma. Cancer. 1997, 79 (9): 1686-1697. 10.1002/(SICI)1097-0142(19970501)79:9<1686::AID-CNCR8>3.0.CO;2-A.View ArticlePubMedGoogle Scholar
- Haier J, Nasralla M, Nicolson G: Cell surface molecules and their prognostic values in assessing colorectal carcinomas. Ann Surg. 2000, 231 (1): 11-24. 10.1097/00000658-200001000-00003.View ArticlePubMedPubMed CentralGoogle Scholar
- Descheny L, Gainers ME, Walcheck B, Dimitroff CJ: Ameliorating skin-homing receptors on malignant T cells with a fluorosugar analog of N-acetylglucosamine: P-selectin ligand is a more sensitive target than E-selectin ligand. J Invest Dermatol. 2006, 126 (9): 2065-2073. 10.1038/sj.jid.5700364.View ArticlePubMedGoogle Scholar
- Urdal DL, Brentrall TA, Bernstein ID, Hakomori S-l: A granulocyte reactive monoclonal antibody, 1G10, identifies the Gal/3-4 (Fuc a 1-3) GlcNAc (X determinant) expressed in HL-60 cells on both glycolipid and glycoprotein molecules. Blood. 1983, 62 (5): 1022-1026.PubMedGoogle Scholar
- Steinberg SM, Barkin JS, Kaplan RS, DM S: Prognostic indicators of colon tumors: the Gastrointestinal Tumor Study Group experience. Cancer. 1986, 57 (9): 1866-1870. 10.1002/1097-0142(19860501)57:9<1866::AID-CNCR2820570928>3.0.CO;2-T.View ArticlePubMedGoogle Scholar
- Herter FP, Slanetz CA: Pattern and significance of lymphatic spread from cancer of the colon and rectum. Lymphatic System Metastasis. Edited by: Weiss L, Gilbert HA, Ballon SC. 1980, Boston: G.K. Hall Medical Publisher, 275-307.Google Scholar
- Ye C, Kiriyama K, Mistuoka C, Kannagi R, Ito K, Watanabe T, Kondo K, Akiyama S, Takagi H: Expression of E-selectin on endothelial cells of small veins in human colorectal cancer. Int J Cancer. 1995, 61 (4): 455-460. 10.1002/ijc.2910610404.View ArticlePubMedGoogle Scholar
- Nakagoe T, Fukushima K, Hirota M, Kusano H, Ayabe H, Tomita M, Kamihira S: Immunohistochemical expression of sialyl Lex antigen in relation to survival of patients with colorectal carcinoma. Cancer. 1993, 72 (8): 2323-2330. 10.1002/1097-0142(19931015)72:8<2323::AID-CNCR2820720807>3.0.CO;2-C.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/9/79/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.